Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
- DOI
- 10.1016/j.annonc.2024.10.002
- Published
- 2025-01
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2024.10.002,
title = {Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study},
author = {D. Lorusso and N. Colombo and C. Dubot and M.V. Cáceres and K. Hasegawa and R. Shapira-Frommer and P. Salman and E. Yañez and M. Gümüş and M. Olivera and V. Samouëlian and V. Castonguay and A. Arkhipov and K. Li and S. Toker and C. Tekin and K.S. Tewari and B.J. Monk},
year = {2025},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2024.10.002},
url = {https://doi.org/10.1016/j.annonc.2024.10.002}
}RIS
TY - JOUR TI - Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study AU - D. Lorusso AU - N. Colombo AU - C. Dubot AU - M.V. Cáceres AU - K. Hasegawa AU - R. Shapira-Frommer AU - P. Salman AU - E. Yañez AU - M. Gümüş AU - M. Olivera AU - V. Samouëlian AU - V. Castonguay AU - A. Arkhipov AU - K. Li AU - S. Toker AU - C. Tekin AU - K.S. Tewari AU - B.J. Monk PY - 2025 JO - Annals of Oncology DO - 10.1016/j.annonc.2024.10.002 UR - https://doi.org/10.1016/j.annonc.2024.10.002 ER -
APA
Lorusso, D., Colombo, N., Dubot, C., Cáceres, M., Hasegawa, K., Shapira-Frommer, R., Salman, P., Yañez, E., Gümüş, M., Olivera, M., Samouëlian, V., Castonguay, V., Arkhipov, A., Li, K., Toker, S., Tekin, C., Tewari, K., & Monk, B. (2025). Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.10.002
Source records
- crossref · retrieved 2026-09-26T11:15:04.754Z